Literature DB >> 24117422

SETBP1 mutations in juvenile myelomonocytic leukaemia and myelodysplastic syndrome but not in paediatric acute myeloid leukaemia.

Norio Shiba1, Kentaro Ohki, Myoung-Ja Park, Manabu Sotomatsu, Kazuko Kudo, Etsuro Ito, Masahiro Sako, Hirokazu Arakawa, Yasuhide Hayashi.   

Abstract

Entities:  

Keywords:  SET binding protein1; acute leukaemia; juvenile myelomonocytic leukaemia; myelodysplastic syndrome

Mesh：

Substances：

Year:  2013        PMID： 24117422     DOI： 10.1111/bjh.12595

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  9 in total

1.  Subclonal mutations in SETBP1 confer a poor prognosis in juvenile myelomonocytic leukemia.

Authors:  Elliot Stieglitz; Camille B Troup; Laura C Gelston; John Haliburton; Eric D Chow; Kristie B Yu; Jon Akutagawa; Amaro N Taylor-Weiner; Y Lucy Liu; Yong-Dong Wang; Kyle Beckman; Peter D Emanuel; Benjamin S Braun; Adam Abate; Robert B Gerbing; Todd A Alonzo; Mignon L Loh
Journal:  Blood       Date:  2014-11-13       Impact factor: 22.113

Review 2.  Somatic SETBP1 mutations in myeloid neoplasms.

Authors:  Hideki Makishima
Journal:  Int J Hematol       Date:  2017-04-26       Impact factor: 2.490

3.  Myeloid progenitors with PTPN11 and nonRAS pathway gene mutations are refractory to treatment with 6-mercaptopurine in juvenile myelomonocytic leukemia.

Authors:  K Matsuda; Y Nakazawa; C Iwashita; T Kurata; K Hirabayashi; S Saito; M Tanaka; K Yoshikawa; R Yanagisawa; K Sakashita; S Sasaki; T Honda; K Koike
Journal:  Leukemia       Date:  2014-02-05       Impact factor: 11.528

Review 4.  Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable.

Authors:  Katerina Zoi; Nicholas C P Cross
Journal:  Int J Hematol       Date:  2014-09-12       Impact factor: 2.490

5.  An International MDS/MPN Working Group's perspective and recommendations on molecular pathogenesis, diagnosis and clinical characterization of myelodysplastic/myeloproliferative neoplasms.

Authors:  Tariq I Mughal; Nicholas C P Cross; Eric Padron; Ramon V Tiu; Michael Savona; Luca Malcovati; Raoul Tibes; Rami S Komrokji; Jean-Jacques Kiladjian; Guillermo Garcia-Manero; Attilio Orazi; Ruben Mesa; Jaroslaw P Maciejewski; Pierre Fenaux; Raphael Itzykson; Ghulam Mufti; Eric Solary; Alan F List
Journal:  Haematologica       Date:  2015-09       Impact factor: 9.941

6.  Alteration of the SETBP1 gene and splicing pathway genes SF3B1, U2AF1, and SRSF2 in childhood acute myeloid leukemia.

Authors:  Hyun-Woo Choi; Hye-Ran Kim; Hee-Jo Baek; Hoon Kook; Duck Cho; Jong-Hee Shin; Soon-Pal Suh; Dong-Wook Ryang; Myung-Geun Shin
Journal:  Ann Lab Med       Date:  2014-12-08       Impact factor: 3.464

Review 7.  SETBP1 mutations as a biomarker for myelodysplasia /myeloproliferative neoplasm overlap syndrome.

Authors:  Katherine Linder; Chaitanya Iragavarapu; Delong Liu
Journal:  Biomark Res       Date:  2017-12-06

8.  Overlapping SETBP1 gain-of-function mutations in Schinzel-Giedion syndrome and hematologic malignancies.

Authors:  Rocio Acuna-Hidalgo; Pelagia Deriziotis; Marloes Steehouwer; Christian Gilissen; Sarah A Graham; Sipko van Dam; Julie Hoover-Fong; Aida B Telegrafi; Anne Destree; Robert Smigiel; Lindsday A Lambie; Hülya Kayserili; Umut Altunoglu; Elisabetta Lapi; Maria Luisa Uzielli; Mariana Aracena; Banu G Nur; Ercan Mihci; Lilia M A Moreira; Viviane Borges Ferreira; Dafne D G Horovitz; Katia M da Rocha; Aleksandra Jezela-Stanek; Alice S Brooks; Heiko Reutter; Julie S Cohen; Ali Fatemi; Martin Smitka; Theresa A Grebe; Nataliya Di Donato; Charu Deshpande; Anthony Vandersteen; Charles Marques Lourenço; Andreas Dufke; Eva Rossier; Gwenaelle Andre; Alessandra Baumer; Careni Spencer; Julie McGaughran; Lude Franke; Joris A Veltman; Bert B A De Vries; Albert Schinzel; Simon E Fisher; Alexander Hoischen; Bregje W van Bon
Journal:  PLoS Genet       Date:  2017-03-27       Impact factor: 5.917

Review 9.  SETBP1 dysregulation in congenital disorders and myeloid neoplasms.

Authors:  Nicoletta Coccaro; Giuseppina Tota; Antonella Zagaria; Luisa Anelli; Giorgina Specchia; Francesco Albano
Journal:  Oncotarget       Date:  2017-04-19
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.